3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Stomach Neoplasms
5
Hyperphagia
3
Pancreatic Neoplasms
2
Malnutrition
2
Neutropenia
1
Neoplasms
1
Mucositis
1
Leukemia, Myeloid, Acute
1
Infections
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Colitis
1
Carcinoma, Hepatocellular
1
Adenocarcinoma Of Esophagus
1
Interventions
pegfilgrastim
30
Filgrastim
29
Cyclophosphamide
10
Docetaxel
8
pegylated granulocyte colony-stimulating factor
7
Etoposide
7
Cytarabine
7
Ciprofloxacin
5
Cefepime
5
eflapegrastim
4
Vancomycin
4
Leucovorin
4
Granulocyte Colony-Stimulating Factor
4
Fluorouracil
4
Doxorubicin
4
Peripheral Blood Stem Cell Transplantation
3
Mitoxantrone
3
Methotrexate
3
Levofloxacin
3
Irinotecan
3
Idarubicin
3
Daunorubicin
3
Cyclosporine
3
Caspofungin
3
Carboplatin
3
trifluridine tipiracil drug combination
2
plerixafor
2
liposomal amphotericin B
2
Vincristine
2
Topotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neutropenia
×
fish oil triglycerides
×
Clear all
NCT00533078
2015-07-23
LUNCH1
Insel Gruppe AG, University Hospital Bern
Phase 2
Completed
14 enrolled